Echo Pharmaceuticals B.V.

Echo Pharmaceuticals B.V., founded in 2006, is a pharmaceutical company based in The Netherlands, which focuses on the formulation, production and the development of pharmaceutical products, which are indicated for the treatment of numerous diseases and for applications such as the treatment of pain, nausea and vomiting, anorexia, spasticity and various other symptoms. Our patented processes enable the formulation of lipophilic compounds improving their bioavailability

Echo Pharmaceuticals production technology has been applied to develop Namisol®, a tablet containing the active ingredient delta-9-tetrahydrocannabinol, also known as Dronabinol, which has been extracted and purified from the Cannabis sativa L.

Echo Pharmaceuticals has collaborations with respected partners such as BMC and Bedrocan B.V.

Cannabinoid standards

Echo Pharmaceuticals has extensive experience in the isolation of cannabinoids from cannabis flos. This experience enables us to produce cannabinoid standards in varying degrees of high purity. (see products & services)

Formulation technology platform

Echo Pharmaceuticals offers formulation knowledge and manufacturing services to process lipophilic compounds according to GMP (Good Manufacturing Practise), into a pharmaceutical product.